MedTrace Logo

A Study of Mucopolysaccharidosis Type IIIB (MPS IIIB)

NCT02493998 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 22

Last updated 2020-03-06

No results posted yet for this study

Summary

Mucopolysaccharidosis type IIIB (MPS IIIB, also known as Sanfilippo Syndrome Type B) is a severe neurodegenerative disorder. The purpose of this study is to learn more about the health problems in patients with MPS IIIB and how to measure these problems over time. It will particularly look at how the disease develops in young children. This is an observational study, so no experimental drug will be given. The results from this study will help us design future studies to measure whether these health problems get better when we give experimental drug for MPS IIIB.

Conditions

  • Mucopolysaccharidosis Type IIIB
  • Mucopolysaccharidosis Type 3 B
  • MPS III B
  • MPS 3 B

Sponsors & Collaborators

  • Allievex Corporation

    lead INDUSTRY

Principal Investigators

  • Allievex Medical Monitor · Allievex Corporation

Eligibility

Min Age
1 Year
Max Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2019-04-30
Completion
2019-04-30

Countries

  • United States
  • Australia
  • Colombia
  • Germany
  • Spain
  • Taiwan
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02493998 on ClinicalTrials.gov